Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
This phase IIb trial studies how well low-dose carvedilol works in preventing heart failure in cancer survivors exposed to high dose anthracyclines for management of childhood cancer. Patients who received high-dose anthracycline chemotherapy are at a much greater risk for developing heart failure compared to survivors who didn't get any anthracycline chemotherapy. Heart failure happens when the heart muscle has been weakened and can't pump blood as well as it should. Carvedilol may help lower the risk of cardiovascular complications.
Research Base: Children's Oncology Group
NCT ID: NCT02717507
NCI Protocol Number: COG-ALTE1621
Status: Active, not recruiting
For more information see ClinicalTrials.gov
Interventions
- Carvedilol
- Laboratory Biomarker Analysis
- Pharmacological Study
- Quality-of-Life Assessment
- Questionnaire Administration
- Pharmacogenomic Study
- Placebo Administration
Condition
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Trial Type
Supportive Care/Symptom Management/PROs
See a list of participating sites on ClinicalTrials.gov